Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7507014 | 1.00 | CYP1A2 (0.54) | CYP1A2EPHX1SLC6A2TAAR1MAOA | |
| Hydrochloric Acid SCHEMBL6791172 | 0.98 | CYP1A2 (0.53) | CYP1A2EPHX1SLC6A2TAAR1MAOA | |
| SCHEMBL7143643 | 0.90 | CYP1A2 (0.45) | CYP1A2EPHX1TAAR1ALDH1A1SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL29484058 | 0.88 | CYP1A2 (0.44) | CYP1A2ANPEPALPIPKMPTGS1 | |
| SCHEMBL13919546 | 0.86 | LTA4H (0.53) | CYP1A2SLC6A2MAOASLC6A3SIGMAR1 | |
| SCHEMBL11528941 | 0.83 | CYP1A2 (0.42) | CYP1A2EPHX1SLC6A2TAAR1MAOA | |
| SCHEMBL6222556 | 0.83 | CYP1A2 (0.41) | CYP1A2EPHX1TAAR1MAOACYP2A6 | |
| SCHEMBL22885976 | 0.80 | CYP1A2 (0.42) | CYP1A2EPHX1SLC6A2TAAR1MAOA | |
| SCHEMBL19354261 | 0.80 | IDO1 (0.43) | CYP1A2EPHX1L3MBTL1ALPIPKM | |
| SCHEMBL19354535 | 0.80 | IDO1 (0.43) | CYP1A2EPHX1L3MBTL1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082877-B1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2019-08-28 | — | — | EP | disclosed |
| US-10351593-B2 | Derivatives of dolastatin 10 and uses thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2019-07-16 | — | — | US | disclosed |
| US-20180141973-A1 | Derivatives of Dolastatin 10 and Uses Thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2018-05-24 | — | — | US | disclosed |
| EP-2861581-B1 | 1,2,3,4-Tetrahydroisoquinoline-pyrrolidine derivatives as antagonists of apoptosis (IAPs) for the treatment of cancer. | BRISTOL MYERS SQUIBB CO (US) | 2017-02-01 | — | — | EP | disclosed |
| US-8889712-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20040006104-A1 | Neutrophil inhibitors to reduce inflammatory response | THE PROCTER & GAMBLE COMPANY | 2004-01-08 | — | — | US | disclosed |
| WO-2002016327-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS NEUTROPHIL INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006104-A1 | Neutrophil inhibitors to reduce inflammatory response | MPO, SERPINB1, NCF1 | CYP1A2 3609/4885EPHX1 590/4885SLC6A2 4250/4885 |
| US-10351593-B2 | Derivatives of dolastatin 10 and uses thereof | PCSK9, DDOST, DHCR7 | CYP1A2 1295/4885EPHX1 2790/4885SLC6A2 2732/4885 |
| US-20180141973-A1 | Derivatives of Dolastatin 10 and Uses Thereof | PCSK9, DDOST, DHCR7 | CYP1A2 1295/4885EPHX1 2790/4885SLC6A2 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.